Newbornscreening SMA - From Pilot Project to Nationwide Screening in Germany

Area of Science:

• Neurology
• Genetics
• Public Health

Background:

• Targeted therapies for spinal muscular atrophy (SMA) are now available.
• Global efforts are underway to integrate SMA screening into routine newborn screening programs.
• Germany implemented nationwide SMA screening in October 2021, following pilot projects from 2018-2021.

Purpose of the Study:

• To report on the initial phase of nationwide newborn screening for spinal muscular atrophy in Germany.
• To assess the transition process and initial outcomes of the screening program.
• To evaluate the timeliness of diagnosis and treatment initiation.

Main Methods:

• Implementation of newborn screening for spinal muscular atrophy nationwide.
• Development of follow-up criteria with key stakeholders.
• Monitoring of diagnostic timelines and treatment initiation.

Main Results:

• False positive findings were initially reported in 3 patients but were subsequently confirmed after laboratory optimization.
• The average first presentation to a neuromuscular center occurred on day 12 of life.
• Therapy initiation for patients with 2 or 3 SMN2 copies occurred on day 26 of life.
• No significant delay in timing was observed compared to the pilot project.

Conclusions:

• Nationwide newborn screening for spinal muscular atrophy in Germany has been successfully implemented.
• The screening program facilitates early diagnosis and timely treatment initiation.
• Ongoing optimization of screening methods ensures diagnostic accuracy and efficient patient management.